S.Biomedics Co. Ltd.
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson's disease; FECS-Ad, which is 1/2a for the treatment of criti… Read more
S.Biomedics Co. Ltd. (304360) - Total Assets
Latest total assets as of March 2025: ₩44.36 Billion KRW
Based on the latest financial reports, S.Biomedics Co. Ltd. (304360) holds total assets worth ₩44.36 Billion KRW as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
S.Biomedics Co. Ltd. - Total Assets Trend (2022–2024)
This chart illustrates how S.Biomedics Co. Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
S.Biomedics Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
S.Biomedics Co. Ltd.'s total assets of ₩44.36 Billion consist of 65.6% current assets and 34.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩4.48 Billion | 0.0% |
| Accounts Receivable | ₩1.86 Billion | 4.2% |
| Inventory | ₩2.33 Billion | 5.2% |
| Property, Plant & Equipment | ₩4.47 Billion | 10.0% |
| Intangible Assets | ₩407.86 Million | 0.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how S.Biomedics Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: S.Biomedics Co. Ltd.'s current assets represent 65.6% of total assets in 2024, an increase from 46.0% in 2022.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, the same as 0.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is cash and equivalents at 0.0% of total assets.
S.Biomedics Co. Ltd. Competitors by Total Assets
Key competitors of S.Biomedics Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
S.Biomedics Co. Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - S.Biomedics Co. Ltd. generates 0.31x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - S.Biomedics Co. Ltd. is currently not profitable relative to its asset base.
S.Biomedics Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.41 | 2.75 | 2.75 |
| Quick Ratio | 2.21 | 2.29 | 2.29 |
| Cash Ratio | 0.54 | 1.28 | 1.28 |
| Working Capital | ₩17.08 Billion | ₩ 12.12 Billion | ₩ 12.12 Billion |
S.Biomedics Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between S.Biomedics Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 73.56 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 39.6% |
| Total Assets | ₩44.60 Billion |
| Market Capitalization | $208.32 Million USD |
Valuation Analysis
Below Book Valuation: The market values S.Biomedics Co. Ltd.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: S.Biomedics Co. Ltd.'s assets grew by 39.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for S.Biomedics Co. Ltd. (2022–2024)
The table below shows the annual total assets of S.Biomedics Co. Ltd. from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩44.60 Billion | +39.61% |
| 2023-12-31 | ₩31.95 Billion | +31.16% |
| 2022-12-31 | ₩24.36 Billion | -- |